Clinical Trial Update: A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety study of esketamine nasal spray for treatment-resistant depression has completed, with results posted in 2024. The study was sponsore…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Esketamine nasal spray (esketamine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Depressive Disorder, Treatment-Resistant | Phase 3 | Status: COMPLETED | Results posted: 2024-02-20